Influence of solvents on the crystal habit and properties of rofecoxib and celecoxib: No evidence of polymorphism

Journal of Pharmaceutical Negative Results

Volumn 1, Issue 2, 2010, Pages 40-50

  Raval, M K ^a   Babu, P R S ^b   Thimmasetty, J ^c   Parikh, R K ^d   Sheth, N R ^a   Subrahmanyam, C V S ^b  

^a SAURASHTRA UNIVERSITY   (India)

^b Osmania University   (India)

^c Bapuji College of Pharmacy   (India)

^d L M COLLEGE OF PHARMACY   (India)

Author keywords

Celecoxib; crystallization; polymorphism; rofecoxib

Indexed keywords

EID: 84872203951     PISSN: 09769234     EISSN: 22297723     Source Type: Journal    
DOI: 10.4103/0976-9234.75704     Document Type: Article

References (18)

1. Wells IJ. Pharmaceutical Preformulation: The Physicochemical properties of Drug Substances. 1st ed. Chichester: Ellis Horwood Ltd, Halsted Press; 1988.
2. Haleblian JK. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J Pharm Sci 1975;64:1269-88.
3. Shell J. X-ray and crystallographic applications in Pharmaceutical research III: Crystal habit quantitation. J Pharm Sci 1963;52:100-1.
4. Brittain HG. Polymorphism in Pharmaceutical Solids. 1st ed. Informa Healthcare. New York: Marcel Dekker Inc; 1999. p. 231-7 and 280-311.
5. Subrahmanyam CV. Essentials of Physical Pharmacy. 1st ed. New Delhi: Vallabh Prakashan; 2003. p. 64-75.
6. Banerjee S, Bandyopadhyay A, Bhattacharjee R, Mukherjee A, Halder A. Serum levels of chloramphenicol in children, rhesus, monkeys, and cats after administration of chloramphenicol palmitate suspension. J Pharm Sci 1971;60:153-5.
7. Shinbyoung AH, Fang G, Kariuki BM, Harris KD. Abundant polymorphism in a system with multiple hydrogen bonding opportunities: Oxalyl dihydrazide. J Am Chem Soc 2006;128: 8441-52.
8. Evans G. A handbook of Bio analysis and drug metabolism. 1st ed. US: CRC Press; 2004. p. 24-6.
9. Hendel J, Brodthages H. Entero-hepatic cycling of methotrexate estimate by use of D-isomer as reference marker. Eur J Clin Pharmacol 1984;26:103-7. (Pubitemid 14152479)
10. http://www.drugbank.ca. Wishart D. Departments of Computing Science and Biological Sciences, University of Alberta. USA. Available from: http://www.drugbank.ca/drugs/DB00533 [last cited on 2010 Sep 18].
11. http://www.medicinenet.com/script/main/hp.asp. WebMD and part of the WebMD Network, San Clemente, Calif, USA. Available from: http://www.medicinenet. com/rofecoxib/article.htm [last cited on 2010 Sep 18].
12. http://www.drugbank.ca. David Wishart, Departments of Computing Science and Biological Sciences, University of Alberta. USA. Available from: http://www.drugbank.ca/drugs/DB00482 [last cited on 2010 Sep 18].
13. http://www.medicinenet.com/script/main/hp.asp. WebMD and part of the WebMD Network, San Clemente, Calif, USA. Available from: http://www.medicinenet. com/celecoxib/article.htm [last cited on 2010 Sep 18].
14. Chawla G, Gupta P, Thilagavathi R, Chakraborti A, Bansal AK. Characterization of solid-state forms of Celecoxib. Eur J Pharm Sci 2003;20:305-17. (Pubitemid 37338536)
15. Press W, Flannery BP, Tenkolsky S, Vetterling WT. Preparation and Characterization of ranitidine hydrochloride crystals. 2nd ed. Numerical Recipes. England: Cambridge University Press; 1986.
16. Shivakumar HG. Influence of solvents on crystallization, crystal habit and properties of some drugs, Ph.D. Thesis, Faculty of Pharmacy, Mangalore University, Mangalore, India; 1997.
17. Ministry of Health and Family Welfare, Indian Pharmacopoeia, 4th ed. Delhi: The Controller of Publications; 1996.
18. Reddy NM, Rehana T, Ramakrishna S, Chowdary KP, Diwan V. β-Cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies, AAPS PharmSci 2004;6:E7.